(Q38024984)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22777251%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

title

Late-stage Parkinson disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22777251%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22777251%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Joaquim Ferreira

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22777251%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Miguel Coelho

series ordinal

1

1 reference

27 August 2017

Joaquim J Ferreira

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

10 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22777251%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

published in

Nature Reviews Neurology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22777251%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22777251%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22777251%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

435-442

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22777251%20AND%20SRC:MED&resulttype=core&format=json

Worldwide occurrence of Parkinson's disease: an updated review

7 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Quantitative measurement of neurological deficit after mild (30 min) transient middle cerebral artery occlusion in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

The evolution of disability in Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Predictors of survival in patients with Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Novel pharmacological targets for the treatment of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Imaging non-dopaminergic function in Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

The diagnosis of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Non-motor symptoms of Parkinson's disease: diagnosis and management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Levodopa in the treatment of Parkinson's disease: current controversies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Impact of the motor complications of Parkinson's disease on the quality of life

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

The clinical progression of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Minimal clinically important change on the unified Parkinson's disease rating scale

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

The clinically important difference on the unified Parkinson's disease rating scale.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Modification of Parkinsonism--chronic treatment with L-dopa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Levodopa and the progression of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Late-stage Parkinson's disease: the Barcelona and Lisbon cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: a study from a population of brain donors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

What predicts mortality in Parkinson disease?: a prospective population-based long-term study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

A 12-year population-based study of psychosis in Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Dementia and survival in Parkinson disease: a 12-year population study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Dementia in Parkinson's disease: a post-mortem study in a population of brain donors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

What contributes to quality of life in patients with Parkinson's disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Mortality and hallucinations in nursing home patients with advanced Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Patterns of motor and non-motor features in Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Staging of brain pathology related to sporadic Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Parkinsonism: onset, progression, and mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Patterns of outcome measurement in Parkinson's disease clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Development and testing of the Parkinson's disease quality of life scale

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Factor analysis of Parkinson's impairment. An evaluation of the final common pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Differential progression of motor impairment in levodopa-treated Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Factors affecting the quality of life of patients with idiopathic Parkinson's disease--a cross-sectional study in an outpatient clinic attendees.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Rate of clinical progression in Parkinson's disease. A prospective study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

A randomized trial of deep-brain stimulation for Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Intermediate scale for assessment of Parkinson's disease. Characteristics and structure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Parkinson's disease: Clinical analysis of 100 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Range of neuropsychiatric disturbances in patients with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Patterns of levodopa response in Parkinson's disease: a clinico-pathological study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Longitudinal study of the motor response to levodopa in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Risk factors for nursing home placement in advanced Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Relationships between age and late progression of Parkinson's disease: a clinico-pathological study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Mortality from Parkinson's disease in England and Wales 1921-89.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Neuropathology of non-motor features of Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Lewy body cortical involvement may not always predict dementia in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

The interplay of cholinergic function, attention, and falls in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Cognitive status correlates with neuropathologic stage in Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Randomized controlled trial of memantine in dementia associated with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

Rivastigmine for dementia associated with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.126

31 March 2020

1 reference

12 December 2020

Overview of the extranigral aspects of Parkinson disease

1 reference

12 December 2020

Treatment of advanced Parkinson's disease: an evidence-based analysis.

1 reference

12 December 2020

The evolution and origin of motor complications in Parkinson's disease

1 reference

12 December 2020

Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group

1 reference

12 December 2020